Global Home Global Home | EUROPE
Czech Republic Czech Republic

 

A New Era in Anti-Infectives

 
 
 

Latest News
..........................................

December 22nd, 2008
Oculus Innovative Sciences Announces Stock Listing Remains on NASDAQ

December 3rd, 2008
Oculus Innovative Sciences Announces Vetericyn(TM) Wound Spray for Animals to be Distributed in over 1,000 PetSmart Stores

December 1st, 2008
Oculus Innovative Sciences Announces Agreement with Bayer Taiwan Co. Ltd. for Development of Microcyn(R) Technology Use in Taiwanese Animal Market

November 25th, 2008
Oculus Innovative Sciences Receives NASDAQ Notification

November 5th, 2008
Oculus Innovative Sciences Reports Record Second Quarter Product Revenue Up 81%

November 3rd, 2008
Oculus Innovative Sciences to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11

October 29th, 2008
Oculus Innovative Sciences Announces Fiscal Second Quarter Financial Results and Corporate Update Release and Conference Call

October 28th, 2008
Oculus Innovative Sciences Introduces Microcyn(R) Wound Care OTC for U.S. Consumer Market

October 21st, 2008
Oculus Innovative Sciences Launches Microcyn(R) Wound Care for U.S. Podiatry Market

October 8th, 2008
Oculus Innovative Sciences Provides Clinical and Business Update

More »

...........................................

 

Oculus Innovative Sciences Netherlands B.V. (a wholly owned subsidiary of Oculus Innovative Sciences, Inc.) was founded at the end of 2003. This European entity directs the marketing, manufacturing and distribution of Microcyn®-based products in Europe, Africa and Eastern markets. The facility is located in Sittard (in the southeastern part of the Netherlands); strategically located for access to our markets. The Sittard region provides an excellent business infrastructure and a regional government with a genuine appreciation of life sciences technologies.

The European organization is focused on generating market awareness of the wound management capabilities of the disruptive Microcyn®-Technology. Dermacyn® Wound Care is a super-oxidized solution for treating acute and chronic wounds (e.g. diabetic foot ulcers and burns). The combination of excellent performance (broadly applicable within a comprehensive wound treatment); unparalleled safety for patient, medical practitioner and environment; and a ready-to-use, extended-shelf-life formula makes Dermacyn® Wound Care a clear revolution. The application has received approval according to the European Medical Devices Directive (93/42/EEC). This CE-certification was obtained in November 2004.

Oculus Innovative Sciences Netherlands has adopted a market acquisition strategy which employs a regionally segmented distributor network. Having launched Dermacyn® Wound Care late 2004, we are currently expanding this network in the European, African and Eastern territories.

 

For more information please contact:

Oculus Innovative Sciences Netherlands B.V.
P.O. Box 5056
6130 PB Sittard
The Netherlands

Customer Service Europe
Telephone: +31- (46) - 4572 300
FAX: +31- (46) - 4572 399
Email: Info.europe@oculusis.com